問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

Digestive System Department

Division of General Internal Medicine

更新時間:2023-09-19

倪衍玄NI, YEN-HSUAN
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

篩選

List

55Cases

2024-07-01 - 2027-11-30

Phase II

Active
A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Lutikizumab (ABT-981) Lutikizumab (ABT-981)

Participate Sites
4Sites

Recruiting4Sites

2018-01-01 - 2023-05-12

Phase II/III

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis (UC)

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting6Sites

2022-11-30 - 2028-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites

2022-11-30 - 2028-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

2024-05-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2025-09-17

Phase II/III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2024-08-01 - 2027-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-02-01 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-06-01 - 2028-11-15

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2029-01-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites